Los Angeles Capital Management & Equity Research Inc. Has $255,000 Holdings in Concert Pharmaceuticals Inc (CNCE)

Share on StockTwits

Los Angeles Capital Management & Equity Research Inc. reduced its position in Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 62.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,344 shares of the biotechnology company’s stock after selling 34,186 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in Concert Pharmaceuticals were worth $255,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Prudential Financial Inc. lifted its position in shares of Concert Pharmaceuticals by 2.0% during the fourth quarter. Prudential Financial Inc. now owns 81,616 shares of the biotechnology company’s stock worth $1,024,000 after purchasing an additional 1,610 shares during the last quarter. California Public Employees Retirement System lifted its position in shares of Concert Pharmaceuticals by 5.7% during the fourth quarter. California Public Employees Retirement System now owns 89,279 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 4,800 shares during the last quarter. MetLife Investment Advisors LLC lifted its position in shares of Concert Pharmaceuticals by 55.5% during the third quarter. MetLife Investment Advisors LLC now owns 13,953 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 4,980 shares during the last quarter. Capital Fund Management S.A. lifted its position in shares of Concert Pharmaceuticals by 44.1% during the third quarter. Capital Fund Management S.A. now owns 20,900 shares of the biotechnology company’s stock worth $310,000 after purchasing an additional 6,400 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Concert Pharmaceuticals by 42.4% during the fourth quarter. Rhumbline Advisers now owns 31,261 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 9,313 shares during the last quarter. 75.73% of the stock is owned by institutional investors.

Several brokerages have recently commented on CNCE. Zacks Investment Research cut shares of Concert Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 5th. BidaskClub raised shares of Concert Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 6th. TheStreet lowered shares of Concert Pharmaceuticals from a “c-” rating to a “d” rating in a research note on Friday, March 1st. HC Wainwright reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Friday, March 1st. Finally, ValuEngine upgraded shares of Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, November 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $23.00.

CNCE opened at $16.47 on Friday. The stock has a market cap of $387.52 million, a P/E ratio of -6.86 and a beta of 1.03. Concert Pharmaceuticals Inc has a fifty-two week low of $10.80 and a fifty-two week high of $24.19.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings data on Thursday, February 28th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.15). Concert Pharmaceuticals had a negative return on equity of 29.33% and a negative net margin of 533.31%. Analysts expect that Concert Pharmaceuticals Inc will post -3.32 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by Equities Focus and is the property of of Equities Focus. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.equitiesfocus.com/2019/03/17/los-angeles-capital-management-equity-research-inc-has-255000-holdings-in-concert-pharmaceuticals-inc-cnce.html.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Recommended Story: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals Inc (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.